File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s40259-023-00589-3
- Scopus: eid_2-s2.0-85150613052
- WOS: WOS:000951830600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Title | Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis |
---|---|
Authors | |
Issue Date | 23-Mar-2023 |
Publisher | Springer |
Citation | BioDrugs, 2023, v. 37, n. 3, p. 409-420 How to Cite? |
Abstract | Objective: We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab. Methods: An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU. Results: Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: - 187.84 USD/SU (P < 0.001); long-term change - 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: - 145.58 (P < 0.001)], the UK [immediate change: - 34.95 (P = 0.010); long-term change: - 4.77 (P < 0.001)], and Hong Kong [long-term change: - 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA. Conclusions: Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed. |
Persistent Identifier | http://hdl.handle.net/10722/329091 |
ISSN | 2023 Impact Factor: 5.4 2023 SCImago Journal Rankings: 1.796 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Peng, K | - |
dc.contributor.author | Blais, JE | - |
dc.contributor.author | Pratt, NL | - |
dc.contributor.author | Guo, JJ | - |
dc.contributor.author | Hillen, JB | - |
dc.contributor.author | Stanford, T | - |
dc.contributor.author | Ward, M | - |
dc.contributor.author | Lai, ECC | - |
dc.contributor.author | Shin, JY | - |
dc.contributor.author | Tong, XN | - |
dc.contributor.author | Fan, M | - |
dc.contributor.author | Cheng, FWT | - |
dc.contributor.author | Wu, J | - |
dc.contributor.author | Yeung, WWY | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Leung, WK | - |
dc.contributor.author | Wong, ICK | - |
dc.contributor.author | Li, X | - |
dc.date.accessioned | 2023-08-05T07:55:13Z | - |
dc.date.available | 2023-08-05T07:55:13Z | - |
dc.date.issued | 2023-03-23 | - |
dc.identifier.citation | BioDrugs, 2023, v. 37, n. 3, p. 409-420 | - |
dc.identifier.issn | 1173-8804 | - |
dc.identifier.uri | http://hdl.handle.net/10722/329091 | - |
dc.description.abstract | <div><p><strong>Objective: </strong> We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab.</p><p><strong>Methods: </strong> An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU.</p><p><strong>Results: </strong> Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: - 187.84 USD/SU (P < 0.001); long-term change - 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: - 145.58 (P < 0.001)], the UK [immediate change: - 34.95 (P = 0.010); long-term change: - 4.77 (P < 0.001)], and Hong Kong [long-term change: - 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA.</p><p><strong>Conclusions: </strong> Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed.</p></div> | - |
dc.language | eng | - |
dc.publisher | Springer | - |
dc.relation.ispartof | BioDrugs | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1007/s40259-023-00589-3 | - |
dc.identifier.scopus | eid_2-s2.0-85150613052 | - |
dc.identifier.volume | 37 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 409 | - |
dc.identifier.epage | 420 | - |
dc.identifier.eissn | 1179-190X | - |
dc.identifier.isi | WOS:000951830600001 | - |
dc.identifier.issnl | 1173-8804 | - |